Form 8-K - Current report:
SEC Accession No. 0001096906-24-000199
Filing Date
2024-02-13
Accepted
2024-02-13 17:16:17
Documents
15
Period of Report
2024-02-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 AXIM BIOTECHNOLOGIES, INC. - FORM 8-K SEC FILING axim-20240207.htm   iXBRL 8-K 19014
  Complete submission text file 0001096906-24-000199.txt   150749

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT axim-20240207_def.xml EX-101.DEF 1842
3 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT axim-20240207_lab.xml EX-101.LAB 20742
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axim-20240207_pre.xml EX-101.PRE 13772
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axim-20240207.xsd EX-101.SCH 2378
16 EXTRACTED XBRL INSTANCE DOCUMENT axim-20240207_htm.xml XML 2676
Mailing Address 6191 CORNERSTONE COURT, E SUITE 114 SAN DIEGO CA 92121
Business Address 6191 CORNERSTONE COURT, E SUITE 114 SAN DIEGO CA 92121 (212) 751-0001
AXIM BIOTECHNOLOGIES, INC. (Filer) CIK: 0001514946 (see all company filings)

EIN.: 274092986 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-54296 | Film No.: 24629850
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)